BonothyrkБонотирк
A peptide mixture made from calf or pig parathyroid glands, studied in an institute report on bone mineral loss.
What the studies found
Comparison in people · 2011
Bonothyrk: institute clinical report (commercially hosted translation)
- Reported category of 15–20% bone mineral density loss
- At three months, 94.7% in the Bonothyrk group and 90.5% in controls, as printed. The table gives a shared baseline of 90.5%.
- Reported category of 20–25% bone mineral density loss
- At three months, 5.3% with Bonothyrk and 14.4% in controls, as printed.
The 33-person report gives bone mineral density loss categories three months after treatment. The printed category percentages conflict with the stated group sizes.
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Study notes · methods, sources and limitations
Participants or model 33 women aged 47–56: 20 preparation, 13 controls
Design 33 women aged 47–56 with climacteric symptoms and reduced bone mineral density. Twenty took two 10 mg capsules twice daily (40 mg/day) for 30 days. Thirteen took no intervention aimed at raising bone density. Densitometry was performed before treatment and three months after the course.
Important limitations
- The signed original has not been authenticated. Allocation and masking are not described. The entry criterion and reported baseline categories are inconsistent. The control percentages do not sum to 100%. The report provides no fracture outcomes or interpretable between-group change in bone mineral density.
- The table percentages cannot be reconciled with the stated group sizes and control percentages sum to 104.9%. The category figures do not provide a reliable between-group effect on bone density.
Institute-attributed report, 2011; commercially hosted brochure pp. 9–10 · Institute report — commercial reproduction
About Bonothyrk
Identity / background source ↗
Research background
Bonothyrk is a calf parathyroid peptide preparation. A Medical Center report assessed bone mineral density in 33 women.
- Compound class
- Archival preparation lead
- Research collection
- Peptide bioregulation · editorial grouping
- Institutions in linked studies
- Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
- Source review
- Review dates and the material assessed are listed with each publication below.
Understanding the evidence
Human research
33 women aged 47–56: 20 preparation, 13 controls
Study methods
Small adjunctive comparison; signed original, allocation and reporting require verification
Independent replication
New citations are not automatically independent replication; shared programs and translated reports require cohort checks
Source access
New indexed primary abstracts and/or report reproductions linked; review depth shown per source
Safety evidence
Reported tolerability is not proof of safety; uncommon harms and long-term outcomes remain unresolved
Open a topic for the evidence assessment.
Findings by study
Tissue-preparation reports: comparisons, source limits and remaining gaps ↗
Comparison in people · 2011
Bonothyrk: institute clinical report (commercially hosted translation)
The 33-person report gives bone mineral density loss categories three months after treatment. The printed category percentages conflict with the stated group sizes.
Reported category of 15–20% bone mineral density loss · At three months, 94.7% in the Bonothyrk group and 90.5% in controls, as printed. The table gives a shared baseline of 90.5%.
Study notes and original source
Bonothyrk: institute clinical report (commercially hosted translation)
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Oral calf parathyroid tissue polypeptide complex · Institute report — commercial reproduction
Format: PDF · Reviewed: Report reproduction reviewed
St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute-attributed report, 2011; commercially hosted brochure pp. 9–10
The 33-person report gives bone mineral density loss categories three months after treatment. The printed category percentages conflict with the stated group sizes.
Results and tables
Reported findings and study design
33 women aged 47–56 with climacteric symptoms and reduced bone mineral density. Twenty took two 10 mg capsules twice daily (40 mg/day) for 30 days. Thirteen took no intervention aimed at raising bone density. Densitometry was performed before treatment and three months after the course.
Population or model 33 women aged 47–56: 20 preparation, 13 controls
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Reported category of 15–20% bone mineral density loss | At three months, 94.7% in the Bonothyrk group and 90.5% in controls, as printed. The table gives a shared baseline of 90.5%. | |
| Reported category of 20–25% bone mineral density loss | At three months, 5.3% with Bonothyrk and 14.4% in controls, as printed. |
The table percentages cannot be reconciled with the stated group sizes and control percentages sum to 104.9%. The category figures do not provide a reliable between-group effect on bone density.
Source for these results ↗ · Reviewed 2026-11-16
- Population / setting
- 33 women aged 47–56: 20 preparation, 13 controls
- Source reviewed
- Russian Medical Center report reproduction, methods and densitometry table.
Study limitations
- The signed original has not been authenticated. Allocation and masking are not described. The entry criterion and reported baseline categories are inconsistent. The control percentages do not sum to 100%.
- The report provides no fracture outcomes or interpretable between-group change in bone mineral density.
Reviewed 2026-11-16.
Related compound research
Follow shared publications or research classes. These links do not establish equivalent effects between compounds.
Research collection curated by @PepMariner · editorial standards. Send a source correction ↗
Browse bibliography & PDFs ↗